Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity

[1] Aberle DR(2011)Reduced lung-cancer mortality with low-dose computed tomographic screening N Engl J Med 365 395-409

[2] Adams AM(2009)Subsolid Pulmonary Nodules and the Spectrum of Peripheral Adenocarcinomas of the Lung: Recommended Interim Guidelines for Assessment and Management Radiology 253 606-622

[3] Berg CD(2011)Ground-glass opacity nodules: histopathology, imaging evaluation, and clinical implications J Thorac Imaging 26 106-118

[4] Black WC(2011)International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 244-285

[5] Clapp JD(2006)Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors J Thorac Oncol 24 1679-1688

[6] Fagerstrom RM(2010)Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388

[7] Gareen IF(2010)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 121-128

[8] Gatsonis C(2011)Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 735-742

[9] Marcus PM(2007)Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer Nature 448 561-566

[10] Sicks J(2010)Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer N Engl J Med 363 1693-1703

[1] Aberle DR(2011)Reduced lung-cancer mortality with low-dose computed tomographic screening N Engl J Med 365 395-409

[2] Adams AM(2009)Subsolid Pulmonary Nodules and the Spectrum of Peripheral Adenocarcinomas of the Lung: Recommended Interim Guidelines for Assessment and Management Radiology 253 606-622

[3] Berg CD(2011)Ground-glass opacity nodules: histopathology, imaging evaluation, and clinical implications J Thorac Imaging 26 106-118

[4] Black WC(2011)International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 244-285

[5] Clapp JD(2006)Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors J Thorac Oncol 24 1679-1688

[6] Fagerstrom RM(2010)Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388

[7] Gareen IF(2010)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 121-128

[8] Gatsonis C(2011)Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 735-742

[9] Marcus PM(2007)Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer Nature 448 561-566

[10] Sicks J(2010)Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer N Engl J Med 363 1693-1703